Gilead Sciences buying Forty Seven for $4.9 billion
|
March 2, 2020 5:05 AM
Gilead Sciences is buying the cancer treatment company Forty Seven in a deal valued at approximately $4.9 billion.
Become a Subscriber!
You have read all of your free articles this month. Select a plan below to start your subscription today.
Already a subscriber? Login
